期刊文献+

p16在重组人肿瘤坏死因子诱导的HepG2肝癌细胞凋亡中的作用研究

The effects of p16 in the apoptosis of HepG2 Hepatocellular carcinoma cells induced by recombinant mutant human tumor necrosis factor (rmhTNF)
下载PDF
导出
摘要 目的:研究p16在重组人肿瘤坏死因子(rmhTNF)诱导的肝癌细胞凋亡中的作用。方法:用rmhTNF处理肝癌细胞,以流式细胞仪检测细胞周期变化,蛋白免疫印迹检测细胞内p16的表达变化。用siRNA干扰p16的表达后,再予流式细胞仪检测细胞的凋亡变化。结果:rmhTNF可以诱导肝癌细胞HepG2的凋亡,同时也可以诱导p16的表达的增加。干扰p16的表达可以逆转由rmhTNF诱导的肝癌细胞的凋亡。结论:p16在rmhTNF诱导的肝癌细胞的凋亡中发挥着重要的作用。 Objective: To investigate the effects of p16 in the apoptosis of HepG2 Hepatocellular carcinoma cells induced by recombinant mutant human tumor necrosis factor (rmhTNF). Methods: HepG2 cells were treated with rmhTNF, cell cycle change was tested by flow eytometry, p16 expression was analyzed by western blot. The apoptosis of HepG2 cells was detected by flow cytometry after pretreatment of p16 with siRNA. Results: Treatment of rmhTNF to HepG2 Hepatocellular carcinoma ceils could induce cell apoptosis and the increased p16 expression. Knockdown p16 expression could reverse rmTNF-induced HepG2 cells apoptosis. Conclusion: p16 plays a critical role in the apoptosis of HepG2 hepatocellular carcinoma cell induced.by rmhTNF.
出处 《交通医学》 2009年第6期611-612,614,共3页 Medical Journal of Communications
关键词 重组人肿瘤坏死因子 肝癌细胞 凋亡 P16 rmhTNF hepatocellular carcinoma cell apoptosis p16
  • 相关文献

参考文献3

二级参考文献31

  • 1陈敏华,严昆,杨薇,高文,戴莹,霍苓,张晖,黄信孚.肝细胞癌256例射频消融治疗5年疗效报告[J].北京大学学报(医学版),2005,37(6):671-672. 被引量:14
  • 2刘新垣 曹蕾.细胞因子在肿瘤治疗中的应用[A].曹世龙.肿瘤学新理论与新技术[C].上海:上海科技教育出版社,1997.154.
  • 3Chcialowski A, Plusa T, Szczylik C, et al .Local treatment with tumor necrosis factor alpha in a patient with lung cancer[J ]. Pol Merkuriusz Lek , 1997,2(12):382-384.
  • 4Yasuoka Y, Naomoto Y, Yamatsuji T, et al. Cxmabination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a C-myc-dependent pathway in P53 mutant H226br non-small-cell lung cancer cell line [J] . Exp Cell Res, 2001,271(2) :214-222.
  • 5Pass HI, Mew DJ, Kranda KC, et al. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases [J]. Ann Thorac Surg,1996,61(6):609-611.
  • 6Tomica AM, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/ endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients [J] .Anticancer Res, 1998, 18:3937-3939.
  • 7Eqqermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with TNF and melphalan for limb salvage in 186 patients with locally advanced soft tissure extremity sarcoma[J].Ann Sure, 1996,224 (6):756-764.
  • 8Eggermont AMM, Schreffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial[J]. Clin Oncol, 1996, 14:2653-2665.
  • 9Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma[J]. Clin Oncol, 1992, 10: 52-60.
  • 10Eggermont AMM. TNF registered in Europe: Does TNF get a second chance? [ J]. J Immunotherapy, 2000, 23: 505-506.

共引文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部